Read by QxMD icon Read

Diabetes, Obesity & Metabolism | Page 2

Richard E Gilbert, Kevin E Thorpe
Three, multi-centre, large-scale, randomised, placebo-controlled trials of cardiovascular outcomes with sodium-glucose linked cotransporter-2 (SGLT2) inhibitors have each shown substantial reductions in hospitalisation for heart failure and progression of chronic kidney disease in patients with type 2 diabetes. However, safety concerns remain for this ostensibly paradigm-shifting drug class. In particular, the FDA has highlighted the risk of acute kidney injury (AKI), a condition associated with high morbidity and mortality...
May 3, 2019: Diabetes, Obesity & Metabolism
Megumi Inoue, Martin Lorenz, Hideya Muto, Roland Wesch, Yasuhiro Hashimoto
This report describes novel clinical data assessing pharmacodynamics of insulin glargine/lixisenatide (iGlarLixi) compared with placebo and insulin glargine alone, to determine pharmacokinetics of lixisenatide, and to assess safety of iGlarLixi in Japanese patients with type 2 diabetes mellitus (T2DM). In a single-center, open-label, randomized, placebo-controlled crossover study, patients received subcutaneous iGlarLixi 5U/5μg and 10U/10μg, placebo, and 5U insulin glargine. The primary endpoint was area under the postprandial plasma glucose (PPG) curve (AUC0-2 )...
May 3, 2019: Diabetes, Obesity & Metabolism
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, Cyril Esnault, Yujin Shuto, Hiroshi Maegawa, Daisuke Koya
AIMS: We investigated the effects of SGLT2 inhibitors vs DPP4 inhibitors on renal function preservation using real-world data of patients with type 2 diabetes in Japan, and identified which subgroups of patients showed greater benefits on renal function preservation with SGLT2 inhibitors vs DPP4 inhibitors. METHODS: We retrospectively analysed claims data recorded in the Medical Data Vision database in Japan of patients with type 2 diabetes (aged ≥18 years) prescribed any SGLT2 inhibitor or any DPP4 inhibitor between May 2014 and September 2016 (identification period), in whom estimated glomerular filtration rate (eGFR) was measured at least twice (baseline, up to 6 months before the index date; follow-up: 9-15 months after the index date) with continuous treatment until the follow-up eGFR...
May 3, 2019: Diabetes, Obesity & Metabolism
Ian D Caterson, Assim A Alfadda, Pernille Auerbach, Walmir Coutinho, Ada Cuevas, Dror Dicker, Carly Hughes, Masato Iwabu, Jae-Heon Kang, Rita Nawar, Ricardo Reynoso, Nicolai Rhee, Georgia Rigas, Javier Salvador, Paolo Sbraccia, Verónica Vázquez-Velázquez, Jason C G Halford
AIMS: Despite increased recognition as a chronic disease, obesity remains greatly underdiagnosed and undertreated. We aimed to identify international perceptions, attitudes, behaviours and barriers to effective obesity care in people with obesity (PwO) and healthcare professionals (HCPs). METHODS: An online survey was conducted in 11 countries. Participants were adults with obesity and HCPs primarily in direct patient care. RESULTS: 14,502 PwO and 2,785 HCPs completed the survey...
April 29, 2019: Diabetes, Obesity & Metabolism
Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, Yoshiro Maezawa, Kenichi Sakamoto, Daigaku Uchida, Susumu Nakamura, Masaya Yamaga, Hidetaka Yokoh, Akina Kobayashi, Shunichiro Onishi, Kazuki Kobayashi, Jun Ogino, Naotake Hashimoto, Hirotake Tokuyama, Fumio Shimada, Emi Ohara, Takahiro Ishikawa, Mayumi Shoji, Shintaro Ide, Kana Ide, Yusuke Baba, Akiko Hattori, Takumi Kitamoto, Takuro Horikoshi, Ryouta Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Minoru Takemoto, L Kristin Newby, Koutaro Yokote
A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study was conducted to evaluate the efficacy of treatment with ipragliflozin (sodium-dependent glucose transporter-2 inhibitor) versus metformin for visceral fat reduction and glycaemic control among Japanese patients with type 2 diabetes treated with sitagliptin, HbA1c levels of 7-10%, and BMI ≥22 kg/m2 . Patients were randomly assigned (1:1) to receive ipragliflozin 50 mg or metformin 1000-1500 mg daily. The primary outcome was change in visceral fat area as measured by computed tomography after 24 weeks of therapy...
April 17, 2019: Diabetes, Obesity & Metabolism
Jeremy Pettus, Jasvinder Gill, Sachin Paranjape, John Stewart, Shilpy Malla, Steven Edelman, Richard M Bergenstal, Bruce Bode
AIMS: This multicentre (N = 104), randomized controlled phase 4 study compared the efficacy and safety of insulin glargine 300 units/mL (Gla-300) with insulin glargine 100 units/mL (Gla-100) in patients with type 1 diabetes (T1D) ( identifier: NCT02688933). MATERIALS AND METHODS: Patients were randomized 1:1 to self-perform morning Gla-300 or Gla-100 injections daily for 16 weeks. The primary endpoint was the percentage of time blood glucose remained in the target range (70-180 mg/dL) during Week 15/16, measured by blinded continuous glucose monitoring...
April 17, 2019: Diabetes, Obesity & Metabolism
Jin Xia, Yiqing Song, Shristi Rawal, Jing Wu, Stefanie N Hinkle, Michael Y Tsai, Cuilin Zhang
AIMS: Emerging evidence suggests that maternal vitamin D status may be associated with gestational diabetes (GDM). However, the temporal relation remains unclear due to the lack of longitudinal data on vitamin D over pregnancy. We aimed to prospectively and longitudinally investigate vitamin D status during early to mid-pregnancy in relation to GDM risk. METHODS: In a nested case-control study of 107 GDM cases and 214 controls within the Fetal Growth Studies-Singleton Cohort, plasma levels of 25-hydroxyvitamin D2 and D3 (25(OH)D) and vitamin D binding protein were measured at gestational weeks 10-14, 15-26, 23-31, and 33-39; we further calculated total, free, and bioavailable 25(OH)D...
April 17, 2019: Diabetes, Obesity & Metabolism
Gian Paolo Fadini, Veronica Sciannameo, Ivano Franzetti, Daniele Bottigliengo, Paola D'Angelo, Carmela Vinci, Paola Berchialla, Salvatore Arena, Raffaella Buzzetti, Angelo Avogaro
BACKGROUND AND AIMS: Based on cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real-world study, we compared the simultaneous reductions in HbA1c, body weight, and systolic blood pressure after initiation of dapagliflozin or GLP-1RA as second or more advanced line of therapy. METHODS: DARWIN-T2D was a retrospective multi-centre study conducted at diabetes specialist clinics in Italy...
April 15, 2019: Diabetes, Obesity & Metabolism
Ilaria Dicembrini, Besmir Nreu, Edoardo Mannucci, Matteo Monami
BACKGROUND: Concerns on the effect of SGLT-2 inhibitors (SGLT-2i) have been risen by some studies, showing an increased incidence of bladder cancer, particularly for empagliflozin. Aim of the present meta-analysis of randomized trials is the assessment of the effects of SGLT-2i on overall incidence of malignancies and on different cancer types, synthetizing the results of trials with a duration of at least one year. METHODS: A Medline and Embase search for "Canaglifozin", "Dapaglifozin", "Empaglifozin", "Ertuglifozin", "Ipraglifozin", Tofoglifozin", or "Luseoglifozin" was performed, collecting randomized trials (duration>52 weeks) up to December 1st , 2018, comparing SGLT-2i with placebo or active comparators...
April 11, 2019: Diabetes, Obesity & Metabolism
Shih-Chang Lo, Edy Kornelius, Jing-Yang Huang, Yung-Rung Lai, Chien-Ning Huang, Yi-Sun Yang, Jeng-Yuan Chiou
OBJECTIVE: Severe hypoglycaemia is associated with a high risk of cardiovascular events in patient with diabetes. The aim of this study is to clarify the temporal relationship between hypoglycaemia and cardiovascular events. RESEARCH DESIGN AND METHODS: This observational cohort study was conducted using Taiwan's Longitudinal Cohort of Diabetes Patients Database, which included 360,000 patients with newly diagnosed diabetes for the period 1999 to 2001. Patients with the first severe hypoglycaemia after 2002 served as the study cohort...
April 11, 2019: Diabetes, Obesity & Metabolism
Martin Adiels, Marja-Riitta Taskinen, Elias Björnson, Linda Andersson, Niina Matikainen, Sanni Söderlund, Juhani Kahri, Antti Hakkarainen, Nina Lundbom, Carina Sihlbom, Annika Thorsell, Haihong Zhou, Kirsi H Pietiläinen, Chris Packard, Jan Borén
AIMS: ApoC-III is an important novel target underpinning the link between hypertriglyceridemia with cardiovascular disease. Here, we investigated how apoC-III metabolism is altered in subjects with type 2 diabetes, and focused on whether the perturbed plasma triglyceride concentrations in this condition are determined primarily by the secretion rate or the removal rate of this apoprotein. Second, we investigated whether improvement of glycemic control using the GLP-1 analogue liraglutide for 16 weeks modifies apoC-III dynamics...
April 10, 2019: Diabetes, Obesity & Metabolism
Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito
Diabetic kidney disease (DKD) still remains a progressive condition that is associated with higher risk of end-stage kidney disease and significant cardiovascular morbidity and mortality. Twelve cardiovascular outcome trials (CVOTs) in type 2 diabetes (T2D) have been so far published. Most trials with dipeptidyl-peptidase inhibitors (SAVOR-TIMI 53 with saxagliptin, EXAMINE with alogliptin, TECOS with sitagliptin, and CARMELINA with linagliptin), and with the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (ELIXA with lixisenatide, LEADER with liraglutide, SUSTAIN-6 with semaglutide, EXCSEL with exenatide once weekly, and HARMONY with albiglutide) pointed toward reduced albuminuria which is a surrogate endpoint possibly heralding renal function preservation...
April 10, 2019: Diabetes, Obesity & Metabolism
Eric Wittbrodt, David Chamberlain, Suzanne V Arnold, Fengming Tang, Mikhail Kosiborod
Generalizability of findings from cardiovascular outcomes trials (CVOTs) to patients with type 2 diabetes (T2D) in clinical practice is unknown. We assessed the proportions of patients in the Diabetes Collaborative Registry who would have met enrolment criteria for pivotal CVOTs of sodium-glucose co-transporter-2 inhibitors (SGLT-2is): EMPA-REG OUTCOME, CANVAS, DECLARE and VERTIS CV. In 172 643 patients, mean [standard deviation (SD)] age and HbA1c were 68.1 (11.8) years and 7.8% (2.2), respectively; 56.8% of patients were men and SGLT-2i use was 4...
April 10, 2019: Diabetes, Obesity & Metabolism
Anna Ferrulli, Concetta Macrì, Ileana Terruzzi, Stefano Massarini, Federico Ambrogi, Michela Adamo, Valentina Milani, Livio Luzi
No abstract text is available yet for this article.
April 8, 2019: Diabetes, Obesity & Metabolism
Christopher Hupfeld, Sunder Mudaliar
The publication of the recent CVOTs (Cardio Vascular Outcome Trials) has transformed the landscape of diabetes treatment. The GLP-1R agonists (GLP-1R agonists) and the SGLT2-Inhibitors have demonstrated CV benefits in large, well conducted, randomized studies. Today, empagliflozin, canagliflozin and liraglutide are FDA approved not only for glucose lowering, but also to reduce the risk of CV events/CV mortality in patients with type 2 diabetes (T2DM) and established CV Disease (CVD)/high CVD risk. Although the CVOTs were primarily powered for CV safety (non-inferiority), they also demonstrated CV efficacy (superiority)...
April 8, 2019: Diabetes, Obesity & Metabolism
Donnie Funch, Kathleen Mortimer, Najat J Ziyadeh, John D Seeger, Ling Li, Heather Norman, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Helge Gydesen, David D Dore
AIMS: Both acute pancreatitis (AP) and pancreatic cancer (PC) have been areas of focus for studies of incretin drugs. This 5-year prospective cohort study aimed to quantify possible associations between liraglutide and risk of AP and PC compared to other antidiabetic drugs (ADs). MATERIALS AND METHODS: Patients initiating liraglutide or other ADs and enrolled in a United States health plan (2010-2014) were included. Comparisons of AP and PC incidence rates were made between matched cohorts of liraglutide initiators and initiators of other ADs...
April 4, 2019: Diabetes, Obesity & Metabolism
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida, Hideki Suganami
AIMS: Little is known about whether sodium intake is associated with the clinical effects of SGLT2 inhibitors (SGLT2is); however SGLT2is may increase urinary sodium excretion. Thus, we investigated the impact of daily sodium intake on the estimated glomerular filtration rate (eGFR) via an SGLT2i, tofogliflozin (TOFO), in patients with type 2 diabetes (T2D). METHODS: Analysis of individual-level data on 775 T2D patients in TOFO Phase 3 trials was performed. Adjusted changes in variables during 52 weeks of TOFO therapy were compared according to basal daily salt intake (DSI), which was measured based on estimated daily urinary sodium excretion using the Tanaka formula...
April 3, 2019: Diabetes, Obesity & Metabolism
Sarah J Hallberg, Nancy E Dockter, Jake A Kushner, Shaminie J Athinarayanan
Clinical Practice Guidelines (CPG) are not new, but they are growing in number. A modern definition of CPG was set forth in 1992 by the Institute of Medicine and updated in 2011: "Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options."1 This article is protected by copyright. All rights reserved.
April 3, 2019: Diabetes, Obesity & Metabolism
Tetsuro Tsujimoto, Hiroshi Kajio
There is little evidence on whether non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin interact in secondary cardiovascular prevention in type 2 diabetic patients. This is an observational study using data from the Action to Control Cardiovascular Risk in Diabetes and Action to Control Cardiovascular Risk in Diabetes Follow-on studies. Hazard ratios (HRs) for mortality with 95% confidence intervals (95%CIs) were calculated using the Cox proportional hazard models to compare the time to death in patients taking and not taking aspirin who were simultaneously taking or not taking NSAIDs...
April 3, 2019: Diabetes, Obesity & Metabolism
E Patorno, C Gopalakrishnan, K G Brodovicz, A Meyers, D B Bartels, J Liu, M Kulldorff, S Schneeweiss
BACKGROUND: There are limited real-world data on the comparative cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) available since May 2011. OBJECTIVES: We aimed to evaluate the safety of linagliptin vs. other glucose-lowering medications in a multi-year monitoring program using insurance claims data. METHODS: In two commercial U.S. claims databases, we identified three pairwise 1:1 propensity score (PS) matched cohorts of type 2 diabetes (T2D) patients ≥18 years initiating linagliptin or a comparator [other DPP-4i (n=31,492 pairs), pioglitazone (n=23,316 pairs), or 2nd generation sulfonylureas (n=19,731 pairs)] between May 2011 and December 2015...
April 2, 2019: Diabetes, Obesity & Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"